(BUSINESS WIRE)--Pfizer Animal Health today announced that the U.S. Food and Drug Administration (FDA) has approved the first canine cancer therapy in the U.S. – PALLADIATM (toceranib phosphate) – which was developed by Pfizer to treat mast cell tumors in dogs. Pfizer made the announcement to veterinarians attending the 2009 American College of Veterinary Internal Medicine (ACVIM) Forum and Canadian Veterinary Medical Association
Press Release Archive
June 3, 2009 - FDA Approves First Canine Cancer Therapy
June 2, 2009 - Pfizer Announces Completion Of European Debt Offering
(BUSINESS WIRE)--Pfizer Inc today announced the successful completion of its offering of €5.85 billion and £1.50 billion of senior unsecured notes (totaling approximately $10.5 billion). The notes consist of: €1.85 billion of 3.625% notes due 2013 €2.00 billion of 4.75% notes due 2016 €2.00 billion of 5.75% notes due 2021 £1.50 billion of 6.50%
(BUSINESS WIRE)--Pfizer Inc announced today that Toviaz™ (fesoterodine fumarate) extended release tablets and the YourWay™ plan (www.ToviazYourWay.com), a comprehensive, customizable support plan for overactive bladder patients, are available in the United States. Toviaz is a once-daily prescription treatment for patients with symptoms of overactive bladder, which include frequent and sudden urges to urinate and wetting
(BUSINESS WIRE)--Pfizer Inc today announced the discontinuation of the SUN 1094 Phase 3 study that evaluated SUTENT® (sunitinib malate) plus paclitaxel versus bevacizumab plus paclitaxel for the first line treatment of patients with advanced breast cancer. The independent Data Monitoring Committee (DMC) found that treatment with sunitinib in combination with paclitaxel would be unable to meet the primary endpoint of superior progression-
(BUSINESS WIRE)--Pfizer announced today results from studies evaluating the company’s investigational anti-insulin growth factor- type 1 receptor (IGF-1R) antibody, figitumumab (CP-751,871), in patients with non-small cell lung cancer (NSCLC). A total of three abstracts were presented at the 45th Annual American Society of Clinical Oncology (ASCO) annual meeting in Orlando. “As we try to find the right drug to use in
--(BUSINESS WIRE)--Pfizer announced today results from four studies highlighting clinical data with targeted treatment approaches in patients with non-small cell lung cancer (NSCLC). Data on the company’s oral c-Met and ALK inhibitor (PF-02341066), an investigational agent that selectively targets cancer-causing genes implicated in the progression of many cancers, will be presented at the 45th American Society of Clinical Oncology (ASCO
(BUSINESS WIRE)--Pfizer announced today, at the 45th American Society of Clinical Oncology (ASCO) Annual Meeting, the results of several clinical studies that may help identify patients who are more likely to benefit when treated with Sutent® (sunitinib malate) or axitinib (AG-013736), an investigational compound. The data identifies prognostic and predictive factors associated with longer overall survival among subgroups of
(BUSINESS WIRE)--Pfizer Inc invites investors, media and the general public to view and listen to a webcast of a conference call with investment analysts at 1:00 p.m. EDT on Friday, June 12, 2009. The purpose of the call is to review Phase 2 data for CP-690,550, Pfizer’s oral JAK-3 inhibitor, that will be presented during the Annual Congress of the European League Against Rheumatism (EULAR). To view and listen to the webcast,
(BUSINESS WIRE)--Pfizer Inc said today that the United Kingdom’s National Institute for Health and Clinical Excellence (NICE) has issued its final appraisal document (FAD) recommending reimbursement for Sutent (sunitinib malate) as a second-line treatment for patients with advanced gastrointestinal stromal tumor (GIST). This recommendation follows NICE’s recently published guidance recommending reimbursement for Sutent for the
(BUSINESS WIRE)--Pfizer Inc announced today that it has entered into licensing agreements with two pharmaceutical companies based in India, strengthening its position in emerging markets and significantly expanding its portfolio of medicines in its Established Products Business Unit. Off-patent medicines, including branded generics, represent one of the fastest growth segments in the global pharmaceutical market. This is especially
(BUSINESS WIRE)--The addition of Pfizer’s Lyrica® (pregabalin) capsules CV to other generalized anxiety disorder (GAD) treatments significantly improved the symptoms of the condition in patients who responded only partially to previous treatments, according to a study presented today at the American Psychiatric Association annual meeting in San Francisco, Ca. In this study, patients treated with Lyrica showed significant improvements
(BUSINESS WIRE)--Pfizer Animal Health today announced that The European Commission has given Pfizer the go-ahead to market its innovative swine vaccine, Improvac®, across the European Union (EU). Improvac®, now approved in 52 countries around the world, provides a reliable reduction of boar taint in male pigs while improving the profitability and sustainability of pig production as well as the welfare of pigs. It represents an
(BUSINESS WIRE)--Pfizer Inc announced today that it will launch an innovative program to help eligible unemployed Americans and their families who have lost their health insurance maintain access to their Pfizer medicines for free. The inspiration for the new program, called MAINTAIN™ (Medicines Assistance for Those who Are in Need), was generated by Pfizer employees who were witnessing friends, family and neighbors struggle to make ends
(BUSINESS WIRE)--Pfizer will present new data highlighting the company’s commitment to a personalized approach to oncology clinical research, which includes the use of targeted agents in specific patient populations in several advanced and difficult-to-treat cancers. These data will be presented later this month at the 45th Annual American Society of Clinical Oncology (ASCO) annual meeting in Orlando from May 29 to June 2.
(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Frank D’Amelio, Chief Financial Officer, at the 34th Annual Deutsche Bank Healthcare Conference on Tuesday, May 19, 2009 at 3:15 p.m. Eastern Daylight Saving Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Deutsche Bank Healthcare Conference” link
(BUSINESS WIRE)--Pfizer Inc announced today that Greg Simon has joined the company as Senior Vice President, Worldwide Policy. He comes to Pfizer from the presidency of FasterCures, where he led efforts to reform policies governing biopharmaceutical discovery and development, with the goal of bringing a greater number of lifesaving medicines more quickly to doctors and patients. “Greg and his record of leadership are well-known
(BUSINESS WIRE)--Pfizer, Inc (NYSE: PFE), the world's premier biopharmaceutical company, and the Wisconsin Alumni Research Foundation (WARF), the private, non-profit patenting and licensing organization for the University of Wisconsin-Madison, announced today that they have signed a license for human embryonic stem (hES) cell patents for the development of new drug therapies. The WARF license provides Pfizer the rights to work
(BUSINESS WIRE)--Pfizer Inc announced today that Freda Lewis-Hall, M.D., has been appointed as Chief Medical Officer and Senior Vice President, Pfizer Inc. Dr. Lewis-Hall will be the senior physician in the company, responsible for enterprise-wide medical, patient safety, regulatory affairs and quality assurance as well as outreach to doctors and other medical professionals. She joins Pfizer from Vertex Pharmaceuticals, where she was
(BUSINESS WIRE)--Patients suffering from post-traumatic peripheral nerve pain treated with Lyrica® (pregabalin) capsules CV experienced significantly reduced pain compared to those taking placebo, according to new data presented today at the American Academy of Neurology annual meeting. The data also showed that patients treated with Lyrica reported less pain interference with sleep and were significantly more likely to report feeling better
(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Jean-Michel Halfon, President and General Manager, Emerging Markets, at the Bernstein Pharmaceutical Emerging Markets Conference on Wednesday, May 6, 2009 at 8:45 a.m. Eastern Daylight Savings Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Bernstein
Pages
Press release archive foot note
Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.
Stay on top of Pfizer breaking news: Get News Alerts by RSS. 
Stock Quote Disclaimer
20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.
 |
If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page. |
Current Stock Price
| . |
. . |
| %Change | . | 52 Wk. High | . |
| Day High | . | 52 Wk. Low | . |
| Day Low | . | Mkt. Cap(Bil) | . |
| Open | . | ||
| Prev Close | . | Symbol | . |
| Vol. | . | Exchange | . |
Online Pfizer Press Kit
Our press kit provides information that might help you write stories or simply find out more about Pfizer.